Press Releases

Filter: Year:

Compugen Announces Lead Therapeutic Candidate COM902 for CGEN-15137/TIGIT Immuno-Oncology Program

Strong clinical rationale for combination of COM701 and COM902 as cancer immunotherapies in addition to monotherapy use

Mar 28, 2017
READ MORE

Compugen to Present CGEN-15001 Autoimmune Product Candidate at Upcoming Conferences

CGEN-15001 Restores Immune Tolerance and Provides Potential Paradigm Shift in Standard of Care for Multiple Autoimmune Diseases

Mar 22, 2017
READ MORE

Compugen Announces Addition of Prof. Miriam Merad to Its Scientific Advisory Board

Prof. Merad is a distinguished leader in myeloid biology for the development of novel cancer immunotherapies

Mar 08, 2017
READ MORE

Compugen’s CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity

New data shows restoration of antigen-specific immune tolerance and re-establishment of immune homeostasis

Jan 04, 2017
READ MORE

Compugen Immune Checkpoint Program Demonstrates Potential for Development of New Cancer Immunotherapy Treatments

New preclinical results for CGEN-15029 presented in late-breaking session at Annual Meeting of the Society for Immunotherapy of Cancer

Nov 11, 2016
READ MORE

Compugen Ltd. Reports 3rd Quarter 2016 Financial Results

Quarterly conference call will be held on November 16, 2016

Nov 07, 2016
READ MORE

Compugen to Host R&D Day on December 7, 2016 in New York

Event to focus on the Company’s immuno-oncology programs

Nov 03, 2016
READ MORE

Compugen Third Quarter Financial Statements to be Released November 7, 2016

Third quarter conference call postponed to November 16 to allow discussion of new CGEN-15029 data to be presented at the Annual Meeting of the Society for Immunotherapy of Cancer

Oct 10, 2016
READ MORE

Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month

Presentation will include new data on CGEN-15029, a Compugen-discovered novel immune checkpoint target, including functional characterization and antibody blockade

Oct 07, 2016
READ MORE

Compugen Discloses Development of Enhanced LINKS Platform Utilized for the Discovery of Myeloid Targets for Cancer Immunotherapy

Myeloid target candidates predicted in silico using enhanced LINKS platform are now being experimentally validated

Aug 30, 2016
READ MORE

Compugen Achieves Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer

Compugen Achieves Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer

Apr 18, 2016
READ MORE

Dr. Elliott Sigal Joins Compugen Ltd. as Strategic Advisor and Prof. Drew Pardoll Appointed Director at Compugen USA, Inc.

Dr. Elliott Sigal Joins Compugen Ltd. as Strategic Advisor and Prof. Drew Pardoll Appointed Director at Compugen USA, Inc.

Apr 07, 2016
READ MORE

Compugen Presents Results for CGEN-15029 Immuno-Oncology Therapeutic Program

Multiple blocking antibodies discovered for Compugen novel immune checkpoint target candidate for treatment of cancer

Feb 29, 2016
READ MORE

Compugen Presents Translational Study Results Supporting CGEN-15001 for the Treatment of Rheumatoid Arthritis

Results of research collaboration with Prof. Iain B. McInnes from Glasgow University presented at the American College of Rheumatology Annual Meeting

Nov 09, 2015
READ MORE

Compugen Discloses New Results Supporting CGEN-15052 as Novel Immune Checkpoint Target Candidate for Treatment of Cancer

Data presented at the Inaugural International Cancer Immunotherapy Conference in New York City

Sep 16, 2015
READ MORE

Compugen to Disclose Novel Cancer Immunotherapy Target Candidate and Comprehensive Target Characterization Infrastructure at Today’s Analyst and Investor Day

CGEN-15029 target candidate is one of Compugen’s five highest priority cancer immunotherapy target programs

Jun 08, 2015
READ MORE

Compugen to Hold Analyst and Investor Day in New York

A live webcast of the presentations will be available via the Company’s website

May 27, 2015
READ MORE

Compugen Obtains Rights to Use Biological Systems and Materials from the US National Institutes of Health

Additional capabilities anticipated to enhance research and development of Compugen’s immuno-oncology programs

Apr 14, 2015
READ MORE

Compugen Announces Planned Relocation of Headquarters to Larger Facilities

New facilities double available space for corporate offices and research and discovery in Israel

Mar 19, 2015
READ MORE

Compugen to Present at Two Oncology Conferences in March

Presentations include experimental data demonstrating potential of Compugen-discovered novel immune checkpoints as targets for cancer immunotherapy

Mar 02, 2015
READ MORE

Compugen Expands and Strengthens Business Development Team

Felix Karim, PhD, joins Company as Vice President Corporate & Business Development

Feb 23, 2015
READ MORE

Compugen Presents New Results Supporting CGEN-15049 as Potential Cancer Immunotherapy Target

Data presented at the Keystone Symposia on Tumor Immunology

Feb 09, 2015
READ MORE

Compugen Discloses Initial Experimental Results for Predicted Antibody Drug Conjugate Targets

Pipeline Program for oncology to be further expanded and diversified with addition of ADC therapeutic programs to ongoing immuno-oncology programs

Jan 05, 2015
READ MORE
Jun 05, 2017

Compugen to Present at 2017 ASCO

Chicago, Illinois
May 14, 2017

Compugen to Present at IMMUNOLOGY 2017

Washington, DC
Apr 02, 2017

Compugen to Present at AACR 2017

Washington, DC
MORE EVENTS
Banner